Advanced Light Source
A
dvanced
L
ight
S
ource
5
.
0
.
2
5
.
0
.
1
5
.
0
.
3
M
B
C
4
.
2
.
2
8
.
2
.
2
8
.
3
.
1
8
.
2
.
1
1
2
.
3
.
1
S
I
B
Y
L
S
M
X
&
S
A
X
S
B
e
r
k
e
l
e
y
C
e
n
t
e
r
f
o
r
S
t
r
u
c
t
u
r
a
l
B
i
o
l
o
g
y
A
L
S
B
i
o
s
c
i
e
n
c
e
s
2
0
2
1
2
.
1
N
C
X
T
2
.
0
.
1
G
e
m
i
n
i
5
.
4
B
S
I
S
B
-
i
n
f
r
a
r
e
d
5
.
3
.
1
X
F
P
3
.
2
.
1
X
F
P
U
C
S
F
M
i
c
r
o
-
C
T
8
.
3
.
2
SIBYLS (12.3.1)
:
Bio-SAXS beamline
Program Established in 2003
Annual Budget:
~3million$/year
43 Publications in 2020:
4 Science, Nature or Cell
9 high impact
(Nature Associated, PNAS)
2020 Utilization:
80 unique labs served
COVID19 Response Led by SIBYLS Staff
4x increase in diagnostic sensitivity to
SARS-CoV-2
Identified New Target for Therapeutic Treatment
Rigid antibodies improve detection of
SARS-CoV-2 – Published
DOE Mission: Bio-Sequestration and Synthetic Biology
SARS-CoV-2 replication-transcription complex
Under Review
Characterize Primitive Rubisco
for Bio-engineering
Rubisco: Primary Plant CO
2
“Fixer”
Nature Plants
2 Protein Rigid Sheets - Nature
Novel Bio-Material
5 year plan – to build a world class Bio-SAXS/WAXS beamline at SIBYLS
Concerns:
If productivity drops due to new/inconsistent shutdowns, how do we maintain momentum for upgrade?
Berkeley Center for Structural Biology
Operating six MX beamlines
(2.0.1,5.0.1/2/3,8.2.1/2)
BCSB staff: 8 FTE
20% of ALS impactful publications are
associated with data collected at
BCSB beamlines
~350 users/year, 500 visits
26,219 crystals were analyzed in 2020
supporting science and drug
discovery programs
100% remote users in the pandemic
Automated data collection pipeline
15+ Groups using our beamlines in the
effort against COVID-19 pandemic
Experimental Drug Target HIV in a Novel Way
(Gilead Sciences Inc.)
SARS-CoV-2 ORF8 mystery protein
Dr. J. Hurley, UC Berkeley
Amgen
Celgene/BMS
Eli Lilly
Genentech
Gilead
GlaxoSmithKline
GNF
Monsanto/Bayer
Novartis
Regeneron
Takeda
Vertex
NIH-NCI
NIH-NINDS
NIH-NLHBI
Fred Hutch CRC
CDC
Georgia Inst. Technology
Scripps Research Inst.
St-Jude Children Res. Hosp.
HHMI Principal investigators (~40/year)
Duke U.
East Carolina U.
Emory U.
Medical U. South Carolina
Rosalind Franklin U.
U. Kentucky
U. Alabama
U. Georgia
U. of Missouri-Kansas City
U. North Carolina
U. Pittsburgh
U. South Carolina
U. South Florida
U. Texas MD Anderson
U. Virginia
Accelero Biostructures
Cocrystal Discovery
IniXium
Nurix
Vividion
(Market Cap > $1T)
Participating Research Team
BCSB external funding (HHMI, PRT, NIH) ~100M
GEMINI beamline
Micron-size crystals
Molecular
Biology
Consortium
ALS Beamline 4.2.2: Mar 2020 – Mar 2021
Pandemic Operations
Samples screened: 4510
Datasets collected: 1254
65% screened/collected by 4.2.2 staff
Significant Covid-19 work with Vir
Biotechnology
Structural mapping immunodominant
sites of SARS-CoV-2 spike protein
SARS-CoV-2 variant immune evasion
Antibodies that resist SARS-CoV-2
viral escape
SARS-CoV-2 ORF8 protein
Remote collection
PDB 7JX6
Fremont Lab WUSTL
L. Picolli, et. al.,
Cell
Jan. 2020*
DOI: 10.1016/j.cell.2020.09.037
E.C. Thompson, et. al.,
Cell
Mar. 2021*
DOI: 10.1016/j.cell.2021.01.037
T. Starr, et. al. Submitted*
*4.2.2. staff authorship
VIR-7831
85% reduction in
hospitalization or
death
Phase 3 trials over
EUA submitted
COVID-19 treatment
ALS 8.3.1 – TomAlberTron - Highlights
TomAlberTron’s User Community
•
1000+ users
,
60+ institutions
•
PRT investment:
$16 M
since 2001
•
Return:
1826 PDB
720 pubs
250 hi-impact
$132+ M (NIH)
$935+ M (Plexxikon)
•
M
e
d
i
a
n
v
i
s
i
t
-
t
o
-
n
e
x
t
-
v
i
s
i
t
i
n
t
e
r
v
a
l
:
1
1
±
8
d
a
y
s
The Future of Light
2000-2020 5000 hours/year
2021-2025 3000 hours/year
2026
0 hours/year
2027
70% flux
APS-U shutdown 2022
"Explore a range of advanced research tools and facilities including the Advanced Light Source, Berkeley Center for Structural Biology, UCSF, Micro-CT, BSISB infrared, XFPALS, MBC, and Biosciences. Stay updated with the latest in bioscience research and technologies."
Uploaded on Mar 03, 2025 | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Advanced Light Source 8.2.1 Berkeley Center for Structural Biology 8.2.2 8.3.1 UCSF 8.3.2 Micro -CT 5.0.2 5.0.3 5.0.1 5.4 BSISB - infrared 5.3.1 XFP ALS MBC 4.2.2 Biosciences 2021 3.2.1 XFP 12.3.1 SIBYLS MX & SAXS 2.1 NCXT 2.0.1 Gemini
COVID19 Response Led by SIBYLS Staff Rigid antibodies improve detection of SARS-CoV-2 Published SARS-CoV-2 replication-transcription complex Under Review SIBYLS (12.3.1): Bio-SAXS beamline Program Established in 2003 4x increase in diagnostic sensitivity to SARS-CoV-2 Identified New Target for Therapeutic Treatment DOE Mission: Bio-Sequestration and Synthetic Biology Annual Budget: ~3million$/year 2 Protein Rigid Sheets - Nature Rubisco: Primary Plant CO2 Fixer Nature Plants 43 Publications in 2020: 4 Science, Nature or Cell 9 high impact (Nature Associated, PNAS) 2020 Utilization: 80 unique labs served Characterize Primitive Rubisco for Bio-engineering Novel Bio-Material
5 year plan to build a world class Bio-SAXS/WAXS beamline at SIBYLS Concerns: If productivity drops due to new/inconsistent shutdowns, how do we maintain momentum for upgrade?
Berkeley Center for Structural Biology SARS-CoV-2 ORF8 mystery protein Dr. J. Hurley, UC Berkeley Operating six MX beamlines (2.0.1,5.0.1/2/3,8.2.1/2) BCSB staff: 8 FTE 20% of ALS impactful publications are associated with data collected at BCSB beamlines ~350 users/year, 500 visits Experimental Drug Target HIV in a Novel Way (Gilead Sciences Inc.) 26,219 crystals were analyzed in 2020 supporting science and drug discovery programs 100% remote users in the pandemic Automated data collection pipeline 15+ Groups using our beamlines in the effort against COVID-19 pandemic
BCSB external funding (HHMI, PRT, NIH) ~100M HHMI Principal investigators (~40/year) Participating Research Team Duke U. East Carolina U. Emory U. Medical U. South Carolina Rosalind Franklin U. U. Kentucky U. Alabama U. Georgia U. of Missouri-Kansas City U. North Carolina U. Pittsburgh U. South Carolina U. South Florida U. Texas MD Anderson U. Virginia NIH-NCI NIH-NINDS NIH-NLHBI Fred Hutch CRC CDC Georgia Inst. Technology Scripps Research Inst. St-Jude Children Res. Hosp. Amgen Celgene/BMS Eli Lilly Genentech Gilead GlaxoSmithKline GNF Monsanto/Bayer Novartis Regeneron Takeda Vertex Accelero Biostructures Cocrystal Discovery IniXium Nurix Vividion (Market Cap > $1T)
Molecular Biology Consortium MBC ALS Beamline 4.2.2: Mar 2020 Mar 2021 COVID-19 treatment Pandemic Operations Samples screened: 4510 Datasets collected: 1254 65% screened/collected by 4.2.2 staff Significant Covid-19 work with Vir Biotechnology VIR-7831 85% reduction in hospitalization or death Phase 3 trials over EUA submitted SARS-CoV-2 ORF8 protein Remote collection PDB 7JX6 Fremont Lab WUSTL Structural mapping immunodominant sites of SARS-CoV-2 spike protein Antibodies that resist SARS-CoV-2 viral escape SARS-CoV-2 variant immune evasion E.C. Thompson, et. al., Cell Mar. 2021* DOI: 10.1016/j.cell.2021.01.037 L. Picolli, et. al., Cell Jan. 2020* DOI: 10.1016/j.cell.2020.09.037 T. Starr, et. al. Submitted* *4.2.2. staff authorship
ALS 8.3.1 TomAlberTron - Highlights Doudna CRISPR PDBs 6 6 8.3.1 cryoEM 2 SLS COVID protection: nanobody aerosol UCSF-Oxford SARS-CoV-2 fragment screen Schoof et al., Science370 (2020) Schuller et al., Science Advancesin press (2021)
TomAlberTrons User Community 1000+ users, 60+ institutions PRT investment: $16 M since 2001 Return: 1826 PDB 720 pubs 250 hi-impact $132+ M (NIH) $935+ M (Plexxikon) Median visit-to-next-visit interval: 11 8 days
2000-2020 5000 hours/year 2021-2025 3000 hours/year 2026 0 hours/year 2027 70% flux The Future of Light APS-U shutdown 2022
